Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

{
  "signal_id": "effac056-0d39-4369-830c-903cdbd1ad2c",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-01-12T20:52:56+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://ts2.tech/en/caris-life-sciences-cai-stock-drops-on-preliminary-2025-results-everlywell-cancer-screening-deal",
    "title": "Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal",
    "excerpt": "Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal.\n\nNEW YORK, Jan 12, 2026, 15:29 (EST) - Trading in the regular session.\n\n* Shares of Caris Life Sciences dropped roughly 9% in afternoon trading following the release of preliminary revenue numbers for 2025.\n* The company estimated fourth-quarter revenue around $281 million and full-year revenue near $800 million, though it warned of significant prior-period adjustments affecting these figures.\n* Caris revealed a new partnership with Everlywell focused on an upcoming early cancer-screening test, with investors awaiting additional details during a JPMorgan conference presentation later Monday.\n\nCaris Life Sciences shares dropped roughly 8.5% to $26.08 in afternoon trading, after fluctuating between $25.35 and $29.77 earlier today.\n\nEverlywell\n\nThe update comes amid J.P. Morgan Healthcare Conference week, a time when healthcare firms typically try to recalibrate expectations ahead of earnings season. Investors are focused on whether Caris can maintain its growth pace without relying on one-off factors.\n\nCaris faces a tight deadline to control the story. The company is set to present at the conference later Monday, but the stock's steep drop signals that traders are looking for more than just a jump in top-line numbers.\n\nCaris reported preliminary fourth-quarter revenue at around...",
    "product": "Caris Detect",
    "summary": "Caris Life Sciences, Ltd. is developing Caris Detect.",
    "category": "is_developing",
    "found_at": "2026-01-12T20:52:56Z",
    "planning": false,
    "image_url": "https://ts2.tech/wp-content/uploads/2026/01/caris-life-sciences-cai-stock-drops-on-preliminary-2025-results-everlywell-cancer-screening-deal-featured.jpg",
    "confidence": 0.9218,
    "product_data": {
      "full_text": "Caris Detect",
      "fuzzy_match": true
    },
    "published_at": "2026-01-12T20:52:56Z",
    "article_sentence": "Caris announced a partnership with Everlywell to develop Caris Detect, a blood-based multi-cancer early detection (MCED) test."
  }
}

curl https://signals.autobound.ai/v1/signals/effac056-0d39-4369-830c-903cdbd1ad2c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'